Skip to main content
Equibles
TEVA logo

TEVA · Teva Pharmaceutical Industries Ltd

Track TEVA — free

Use TEVA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TEVA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$39.60 -0.21 (-0.53%) At close · Sep 30
Rebalance outlook locked
Market Cap
$45.67B
Shares
1.17B
Volume · Sep 30 5.65M Avg daily vol (3M) 5.31M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$39.81 Open$38.90 Day$38.67–40.24 52W close$18.95–40.22 Avg vol 30d5.2M Short int31.5M · 2.7% float · 27.4d Short vol49% Last earningsNov 3, 2026 DataJan 2020–Sep 2026 Filing10-Q · Jul 29

Up next

Next earnings call
Nov 3, 2026 Scheduled · in 5 wks
Latest filing: 10-Q
filed Jul 29, 2026
Q2 2026 earnings call transcript
call held Jul 29, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$14.10B
Trailing 12 months
Net income (TTM)
$707.00M
Trailing 12 months
Revenue growth YoY
-0.8%
Year over year
Operating margin
11.4%
Trailing 12 months
P / E (TTM)
65.3
Trailing earnings · reciprocal yield 1.5%
FCF yield
3.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.3%
Year over year · more shares
Price change (1Y)
+107.6%
Trailing year
Short interest
2.7%
Latest settlement · 27.4 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 16 · calm Equity put/call 0.38
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +19%
above
Price vs 50-day avg +9%
above
RSI (14) 60
neutral
MACD trend Positive
52-week position 98%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +10%
trailing
6-month return +30%
trailing
YTD return +28%
this year
Relative strength +17%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $36 › 200d $34 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +83 funds added
Insider flow Distributing
Net -$15.0M over 90 days · 100% sells
Short interest Rising
2.70% of float · ▲ +11467.5% MoM · 27.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
682 holders — near 3-yr high, broad support
Squeeze score 79
high risk · 0–100
Fundamentals
Strong
Revenue growth +4%
Y/Y
Gross margin 52%
expanding
EPS growth +183%
Y/Y
Free cash flow $1.1B
Valuation P/E 64.3
rich
Buyback $2.1B
authorized
Balance sheet $27.9B
net debt
Quant / Vol
risk profile
Moderate
Volatility 39%
annualized · 1-yr
Max drawdown −22%
past year
ATR 3.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Jul 29, 2026
Revenues · 2026 $16.5B – $16.85B
prior FY $17.26B midpoint −3.4% Y/Y
Non-GAAP operating income · 2026 Non-GAAP $3.8B – $4B
Adjusted EBITDA · 2026 Non-GAAP $4.23B – $4.53B
Non-GAAP diluted EPS · 2026 Non-GAAP $1.91 – $2.11
Combined key innovative brands revenue (AUSTEDO, AJOVY, UZEDY) · 2026 $3.7B
Guided vs delivered · last 1 settled
Revenues Full year 2024
guided $15.7B – $16.3B
$16.54B Beat +3.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+19% Bullish
Price vs 50-day avg
+9% Bullish
RSI (14)
60 Neutral
MACD trend
Positive Bullish
52-week position
98% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $36 › 200d $34 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +83 funds added
Insider flow Distributing
Net -$15.0M over 90 days · 100% sells
Short interest Rising
2.70% of float · ▲ +11467.5% MoM · 27.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
682 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $19 Now $40 · 98% Range high $40
vs 200-day avg +19% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TEVA
Teva Pharmaceutical Industries Ltd
this stock
$45.67B +27.6% +4.3% 64.3 2.7%
TAK
Takeda Pharmaceutical Co Ltd
 $60.23B +18.7% — — 0.1%
GALDY
Galderma Group AG/ADR
 $46.00B -3.8% — — 0.0%
HLN
Haleon plc
 $40.72B -10.3% — — 0.5%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
 $38.16B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
682
% held
65.4%
Net QoQ
+56.8M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
329
View
Short & Settlement
Short Interest Rising
Shares short
31.5M
Days to cover
27.4d
Change
+31.2M sh
View
Short Volume
Short vol %
49%
As of
Sep 30, 2026
Short Total
View
Fails to Deliver
FTD shares
12.8K
Value
$473.4K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
45.1%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$15.0M
Buyers / Sellers
0 / 5
Buyers Sellers
View
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 30, 2026
View
Financials
Financials
Revenue (FY)
$17.3B
Net income (FY)
$1.4B
EPS diluted
$1.21
View
Buybacks
Authorized
$2.1B
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 16, 2026
This year
17
View
Proposed Sales
Value
$273.1K
Shares
7.0K
Filed
Sep 21, 2026
View
Earnings & Events
Earnings Calls Upcoming
Next call
Nov 3, 2026
Last call
Sep 23, 2026
View
Investor Relations
Latest news
Teva Continues Biosimilar Momentu…
Published
Sep 28, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
TEVA +0.7% +10.4% +30.4% +10.4% +27.6%
SPY -1.2% -0.4% +13.1% -0.4% +12.1%
vs SPY +1.9% +10.8% +17.4% +10.8% +15.5%

Capital returns

Buyback program · as of Dec 31, 2017
Authorized
$2.10B
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 818686 CUSIP 881624209 13F (30d) 15 filings 13 filers Visit website Investor relations